EMERGENT BIOSOLUTIONS INC. Finite-lived Intangible Assets Acquired
EMERGENT BIOSOLUTIONS INC. (EBS) reported Finite-lived Intangible Assets Acquired of $10.00 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-07-31.
Discontinued › Notes › Goodwill and Other
us-gaap:FinitelivedIntangibleAssetsAcquired1 · last filed 2020-07-31
- EMERGENT BIOSOLUTIONS INC. finite-lived intangible assets acquired for the quarter ending 2020-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. finite-lived intangible assets acquired for the quarter ending 2020-03-31 was $10.00M, a 0.00% change year-over-year.
- EMERGENT BIOSOLUTIONS INC. finite-lived intangible assets acquired for the quarter ending 2019-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. finite-lived intangible assets acquired for the quarter ending 2019-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. finite-lived intangible assets acquired for fiscal 2019 was $10.00M, a 98.50% decline from fiscal 2018.
- EMERGENT BIOSOLUTIONS INC. finite-lived intangible assets acquired for fiscal 2018 was $667.00M, a 607.29% increase from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. finite-lived intangible assets acquired for fiscal 2017 was $94.30M.
- EMERGENT BIOSOLUTIONS INC. finite-lived intangible assets acquired for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
| Period end | Finite-lived Intangible Assets Acquired 3 month | Finite-lived Intangible Assets Acquired 6 month | Finite-lived Intangible Assets Acquired 9 month | Finite-lived Intangible Assets Acquired 12 month | Finite-lived Intangible Assets Acquired 12 month as first filed |
|---|---|---|---|---|---|
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $10.00M 10-Q · filed 2020-07-31 | $10.00M derived: sum of 3 quarters · filed 2020-07-31 | $10.00M derived: sum of 4 quarters · filed 2020-07-31 | |
| 2020-03-31 | $10.00M 10-Q · filed 2020-05-01 | $10.00M derived: sum of 2 quarters · filed 2020-05-01 | $10.00M derived: sum of 3 quarters · filed 2020-05-01 | $10.00M derived: sum of 4 quarters · filed 2020-05-01 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $10.00M 10-K · filed 2020-02-25 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $10.00M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $10.00M 10-Q · filed 2019-08-02 | |||
| 2019-03-31 | $10.00M 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | $667.00M 10-K · filed 2020-02-25 | $667.00K 10-K · filed 2019-02-22 | |||
| 2017-12-31 | $94.30M 10-K · filed 2018-02-23 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-05 | ||||
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 | ||||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $0.00 10-Q · filed 2016-08-05 | $0.00 derived: sum of 3 quarters · filed 2016-08-05 | $0.00 derived: sum of 4 quarters · filed 2016-08-05 | |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-06 | $0.00 derived: sum of 2 quarters · filed 2016-05-06 | $0.00 derived: sum of 3 quarters · filed 2016-05-06 | $8.30M derived: sum of 4 quarters · filed 2016-05-06 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $8.30M derived: sum of 3 quarters · filed 2016-02-29 | $8.30M 10-K · filed 2016-02-29 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $8.30M derived: sum of 2 quarters · filed 2015-11-06 | $8.30M 10-Q · filed 2015-11-06 | -$76.70M derived: sum of 4 quarters · filed 2015-11-06 | |
| 2015-06-30 | $8.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $8.30M 10-Q · filed 2015-08-06 | -$76.70M derived: sum of 3 quarters · filed 2015-08-06 | -$36.30M derived: sum of 4 quarters · filed 2015-08-06 | |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | -$85.00M derived: sum of 2 quarters · filed 2015-05-08 | -$44.60M derived: sum of 3 quarters · filed 2015-05-08 | -$4.20M derived: sum of 4 quarters · filed 2015-05-08 | |
| 2014-12-31 | -$85.00M derived: 10-K 12 month − 3 quarters · filed 2015-03-09 | -$44.60M derived: sum of 2 quarters · filed 2015-03-09 | -$4.20M derived: sum of 3 quarters · filed 2015-03-09 | $36.20M 10-K · filed 2015-03-09 | |
| 2014-09-30 | $40.40M 10-Q · filed 2014-11-10 | $80.80M derived: sum of 2 quarters · filed 2014-11-10 | $121.20M derived: sum of 3 quarters · filed 2014-11-10 | ||
| 2014-06-30 | $40.40M 10-Q · filed 2014-08-08 | $80.80M derived: sum of 2 quarters · filed 2014-08-08 | |||
| 2014-03-31 | $40.40M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |